Galmed Pharmaceuticals Ltd (GLMD) - Total Liabilities
Based on the latest financial reports, Galmed Pharmaceuticals Ltd (GLMD) has total liabilities worth $2.85 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Galmed Pharmaceuticals Ltd - Total Liabilities Trend (2012–2025)
This chart illustrates how Galmed Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Galmed Pharmaceuticals Ltd to evaluate short-term liquidity relative to the company's equity base.
Galmed Pharmaceuticals Ltd Competitors by Total Liabilities
The table below lists competitors of Galmed Pharmaceuticals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
USA | $1.46 Million |
|
Wi2Wi Corporation
V:YTY
|
Canada | CA$5.74 Million |
|
Pensionbee Group PLC
LSE:PBEE
|
UK | GBX4.20 Million |
|
Accord Financial Corp.
TO:ACD
|
Canada | CA$140.57 Million |
|
Madoro Metals Corp
V:MDM
|
Canada | CA$62.26K |
|
Cooper Metals Ltd
AU:CPM
|
Australia | AU$58.06K |
|
SIMFABRIC SA ZY-10
F:853
|
Germany | €1.39 Million |
|
Euroespes S.A.
MC:EEP
|
Spain | €5.22 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Galmed Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Galmed Pharmaceuticals Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Galmed Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Galmed Pharmaceuticals Ltd (2012–2025)
The table below shows the annual total liabilities of Galmed Pharmaceuticals Ltd from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.85 Million | +30.92% |
| 2024-12-31 | $2.17 Million | -20.98% |
| 2023-12-31 | $2.75 Million | -12.36% |
| 2022-12-31 | $3.14 Million | -48.62% |
| 2021-12-31 | $6.11 Million | -25.77% |
| 2020-12-31 | $8.23 Million | +12.93% |
| 2019-12-31 | $7.29 Million | +169.25% |
| 2018-12-31 | $2.71 Million | -29.68% |
| 2017-12-31 | $3.85 Million | -28.41% |
| 2016-12-31 | $5.38 Million | +97.76% |
| 2015-12-31 | $2.72 Million | +79.05% |
| 2014-12-31 | $1.52 Million | -28.29% |
| 2013-12-31 | $2.12 Million | -22.77% |
| 2012-12-31 | $2.74 Million | -- |
About Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have… Read more